GLP-1 Market Size Worth USD 133.92 Billion by 2034 | CAGR: 10.9%

The GLP-1 Market market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report “GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism by allowing insulin release and incorporating glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. The growing integration of these therapies into broader chronic disease management frameworks extends their relevance beyond type 2 diabetes to conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/glp-1-market/request-for-sample

The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies that improve metabolic outcomes with fewer side effects and lower dosing frequency. Alongside this, a growing focus on individualized treatment protocols is encouraging the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.

Top of FormGLP-1 Market Report Highlights

• In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2024, for their extended dosing intervals, better patient compliance, and consistent clinical outcomes.
• Based on route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period, driven by increasing preference for needle-free, convenient treatment alternatives.
• In 2024, North America accounted for the largest revenue share, supported by high diabetes/obesity rates, cutting-edge healthcare systems, and rapid uptake of innovative therapies.
• Asia Pacific is poised for the highest growth, fueled by surging lifestyle-related metabolic disorders and expanding healthcare accessibility.
• A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Polaris Market Research has segmented the market report on the basis of route of administration, type of molecule, active compound used, type of GLP-1 agonist drug, target indication, and region:

By Type of Molecule Outlook (Revenue, USD Billion, 2020–2034)

• Biologics
• Small Molecules

By Active Compound Used Outlook (Revenue, USD Billion, 2020–2034)

• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds

By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2020–2034)

• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist

By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)

• Oral
• Parenteral

By Target Indication Outlook (Revenue, USD Billion, 2020–2034)

• Alzheimer’s Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America

• US
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Vietnam
• Australia
• Rest of Asia Pacific

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa